Health inequalities in respiratory tract infections – beyond COVID-19 DOI
Marina Ulanova

Current Opinion in Infectious Diseases, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 20, 2024

Purpose of review To discuss recent findings on the global burden respiratory tract infections in underprivileged populations, highlighting critical role socioeconomic factors incidence and severity these diseases, with a particular focus health disparities affecting Indigenous communities. Recent Pulmonary tuberculosis lower infections, particularly those caused by Streptococcus pneumoniae syncytial virus (RSV), continue to disproportionally impact populations low-income countries communities worldwide. children <5 years old bear highest RSV infection, reflecting persistent social inequalities between non-Indigenous populations. Repeated episodes acute pneumonia during childhood significantly contribute high prevalence chronic diseases among The widespread occurrence bronchiectasis is closely linked adverse conditions. Summary Significant affluent impoverished are driven inequalities. Vaccinating vulnerable population groups newly developed vaccines has potential prevent pathogens such as S. RSV. However, access monoclonal antibodies remains limited due their costs.

Language: Английский

Respiratory syncytial virus infections in adults: a narrative review DOI
Joanne Wildenbeest, David M. Lowe, Joseph F. Standing

et al.

The Lancet Respiratory Medicine, Journal Year: 2024, Volume and Issue: 12(10), P. 822 - 836

Published: Sept. 9, 2024

Language: Английский

Citations

11
Proof-of-principle of a technology transfer of a dried blood virus neutralisation assay to a Gavi-eligible country DOI Creative Commons
Evangeline Obodai, Jonne Terstappen,

Jude Yayra Mensah

et al.

BMJ Global Health, Journal Year: 2025, Volume and Issue: 10(3), P. e016916 - e016916

Published: March 1, 2025

Global health clinical research is commonly led by high-income countries (HICs) as low- and middle-income (LMICs) face barriers to participate, including lack of financial human capacity environment. Respiratory syncytial virus (RSV) vaccine development also HICs, while LMICs carry the burden life-threatening disease. Representative trials strengthening in are needed ensure global access equity. This study aims transfer an RSV neutralisation assay, which uses live cells with inherent high variation, a country eligible receive support from Gavi, Vaccine Alliance. Using train-the-trainer approach, Ghanaian researcher was trained Netherlands on dried blood-based assay. Subsequently, Dutch visited Ghana process adapting technique setting. In previously validated assay blood, Hep-2 were infected serial dilution sample-virus mixture determine half-maximal inhibitory concentration. Fifty-one blood serum samples tested parallel both assess concordance. Training technology deemed successful, defined measurements team concordance (Lin's correlation coefficient (CCC)>0.8). Neutralising measured identical correlated highly CCC=0.87; Spearman rho=0.89) but systematically lower than Netherlands. We show successful thereby laboratory Gavi-eligible country. Reliable measurement neutralising antibodies use can contribute inclusion access.

Language: Английский

Citations

0
Plattformtechnologien in der Impfstoffentwicklung DOI Creative Commons
Eberhard Hildt

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, Journal Year: 2025, Volume and Issue: unknown

Published: March 4, 2025

Zusammenfassung Als Plattformtechnologien im engeren Sinn werden nachfolgend Ansätze der Impfstoffentwicklung bezeichnet, bei denen Impfstoff stets auf einem identischen Grundgerüst basiert und sich nur hinsichtlich des Antigens unterscheidet. Ein Vorteil von besteht in raschen Anpassbarkeit dieser Technologien für die Entwicklung eines Impfstoffs gegen neuartige Erreger oder Varianten. Bei derzeit EU zugelassenen Impfstoffen virale Vektoren mRNA als Plattformen verwendet. dienen dabei rekombinante Adenoviren (Ad), das vesikuläre Stomatitis-Virus (VSV) modifizierte Vacciniavirus Ankara (MVA). Die Applikation mRNA-basierten erfolgt Form Lipidnanopartikeln (LNPs). Funktion LNPs dem Schutz vor Abbau, Förderung Aufnahme Zellen einer Adjuvanswirkung.

Citations

0
Impact and Effectiveness of Universal Respiratory Syncytial Virus Vaccination During Pregnancy on Infant Hospitalizations in Buenos Aires: A Retrospective Cohort Study DOI

Josefina Lorena Razzini,

Daniela Parada, Guillermo Solovey

et al.

Published: March 21, 2025

Language: Английский

Citations

0
Prophylaxis of RSV Infection in Infants DOI
Jennifer L. Nayak, Michael T. Quinn

Current Clinical Microbiology Reports, Journal Year: 2025, Volume and Issue: 12(1)

Published: April 10, 2025

Language: Английский

Citations

0
Technology transfer of a dried blood virus neutralization assay to a GAVI-eligible country DOI Creative Commons
Evangeline Obodai, Jonne Terstappen,

Jude Yayra Mensah

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: July 24, 2024

ABSTRACT Background Global health clinical research is commonly led by high-income countries (HICs) as low- and middle-income face barriers to participate, including lack of financial human capacity environment. Respiratory syncytial virus (RSV) vaccine development also HICs, preventing global access while LMICs carry the burden life-threatening disease. This study aims transfer an RSV neutralization assay, which uses live cells with inherent high variation, a GAVI-eligible country. Methods Using train-the-trainer approach, Ghanaian researcher was trained in Netherlands on dried blood-based assay. Subsequently, Dutch visited Ghana support process adapting technique setting. In previously validated assay blood, Hep-2 were infected serial dilution sample-virus mixture determine half-maximal inhibitory concentration. Fifty-one blood serum samples tested parallel both assess concordance. Results Training technology deemed successful, defined measurements team concordance (Lin’s correlation coefficient (CCC) > 0.8). Neutralizing measured identical correlated highly CCC = 0.87; Spearman rho 0.89) but systematically lower than Netherlands. Conclusion We show successful strengthening laboratory Reliable measurement neutralizing antibodies country use can contribute inclusion access. Funding None KEY MESSAGES What already known? The divide evident respiratory development, where vaccines are developed available (HICs), despite (LMICs) bearing majority disease burden. Representative trials needed ensure equity. this adds? newly established partnership, we used approach low-tech live-virus from Ghana, A sample panel showed difficulties running bioassay inherently variability using distinct materials. How might affect research, practice, or policy? will leverage serve hub Africa supporting other perform analysis management trial samples, ultimately reducing access, thereby advancing sustainable goals.

Language: Английский

Citations

0
Health inequalities in respiratory tract infections – beyond COVID-19 DOI
Marina Ulanova

Current Opinion in Infectious Diseases, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 20, 2024

Purpose of review To discuss recent findings on the global burden respiratory tract infections in underprivileged populations, highlighting critical role socioeconomic factors incidence and severity these diseases, with a particular focus health disparities affecting Indigenous communities. Recent Pulmonary tuberculosis lower infections, particularly those caused by Streptococcus pneumoniae syncytial virus (RSV), continue to disproportionally impact populations low-income countries communities worldwide. children <5 years old bear highest RSV infection, reflecting persistent social inequalities between non-Indigenous populations. Repeated episodes acute pneumonia during childhood significantly contribute high prevalence chronic diseases among The widespread occurrence bronchiectasis is closely linked adverse conditions. Summary Significant affluent impoverished are driven inequalities. Vaccinating vulnerable population groups newly developed vaccines has potential prevent pathogens such as S. RSV. However, access monoclonal antibodies remains limited due their costs.

Language: Английский

Citations

0